孟鲁司特联合舒利迭治疗儿童咳嗽变异性哮喘的临床研究  

Clinical research of montelukast combined seretide treatment of children with cough variant asthma

作　　者：黄金珍[1] 

机构地区：[1]江苏省昆山市千灯人民医院儿科,江苏昆山215341

出　　处：《中国现代医生》2013年第13期65-66,共2页China Modern Doctor

摘　　要：目的探讨孟鲁司特联合舒利迭治疗儿童咳嗽变异性哮喘的临床效果。方法选择2012年1～12月在我院住院的儿童咳嗽变异性哮喘患者共64例,全部患者分为对照组31例(应用舒利迭治疗),治疗组33例(应用孟鲁司特联合舒利迭治疗),比较两组的疗效及咳嗽症状积分治疗前后的变化情况。结果治疗组总有效率为93.9%,仅2例无效,对照组总有效率达71.0%,无效例数比治疗组多7例,两组总有效率比较,差异有统计学意义(P<0.01)。治疗前两组的咳嗽症状积分比较,差异无统计学意义(P>0.05),治疗后,治疗组与对照组治疗后咳嗽症状积分均较治疗前明显降低,差异有统计学意义(P<0.05);且治疗组治疗后与对照组比较其咳嗽症状积分降低更显著,差异均有统计学意义(P<0.05)。结论孟鲁司特联合舒利迭治疗儿童咳嗽变异性哮喘明显缓解患儿的临床症状,提高了单一应用激素治疗的临床疗效,且不良反应少,值得临床推广。Objective To investigate the clinical effects of montelukast joint seretide treatment of children with cough variant asthma. Methods Selected cough variant asthma patients 64 cases in our hospital from January 2012 to De cember 2012, all patients were divided into control group of 31 cases （applications Seretide）, the treatment group of 33 cases （Montelukast combined seretide treatment）. The efficacy and cough symptom score changes before and after treatment were compared between the two groups. Results The total effective rate of the treatment group was 93.9%, the total effective rate of the control group was 71.0%, the difference was significant（P 〈 0.01 ）. Before treatment, the cough symptom score comparison had no significant difference （P 〉 0.05）. After treatment, the treatment group was significantly lower than before treatment and the control group, the differences were statistically significant （P 〈 0.05）. Conclusion Montelukast united seretide treatment of children with cough variant asthma significantly alleviate clinical symptoms in children, improve the clinical efficacy of a single application of hormone therapy, and adverse reactions less, and it is worthy of promotion.

关 键 词：儿童咳嗽变异性哮喘 孟鲁司特 舒利迭 咳嗽症状积分 复发 

分 类 号：R725.6[医药卫生—儿科]